Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model
Department of Medicine; RNA Therapeutics Institute; Department of Quantitative Health Sciences; Program in Molecular Medicine
Immune System Diseases | Immunity | Nervous System Diseases | Translational Medical Research
BACKGROUND: The immune system In Huntington's disease (HD) is activated and may overreact to some therapies. RNA interference using siRNA lowers mutant huntingtin (mHTT) protein but could increase immune responses.
OBJECTIVE: To examine the innate immune response following siRNA infusion into the striatum of wild-type (WT) and HD transgenic (YAC128) mice.
METHODS: siRNAs (2'-O-methyl phosphorothioated) were infused unilaterally into striatum of four month-old WT and YAC128 mice for 28 days. Microglia number and morphology (resting (normal), activated, dystrophic), cytokine levels, and DARPP32-positive neurons were measured in striatum immediately or 14 days post-infusion. Controls included contralateral untreated striatum, and PBS and sham treated striata.
RESULTS: The striata of untreated YAC128 mice had significantly fewer resting microglia and more dystrophic microglia than WT mice, but no difference from WT in the proportion of activated microglia or total number of microglia. siRNA infusion increased the total number of microglia in YAC128 mice compared to PBS treated and untreated striata and increased the proportion of activated microglia in WT and YAC128 mice compared to untreated striata and sham treated groups. Cytokine levels were low and siRNA infusion resulted in only modest changes in those levels. siRNA infusion did not change the number of DARPP32-positive neurons.
CONCLUSION: Findings suggest that siRNA infusion may be a safe method for lowering mHTT levels in the striatum in young animals, since treatment does not produce a robust cytokine response or cause neurotoxicity. The potential long-term effects of a sustained increase in total and activated microglia after siRNA infusion in HD mice need to be explored.
UMCCTS funding, Huntington’s disease, cytokines, immune response, microglia, siRNA
DOI of Published Version
J Huntingtons Dis. 2015;4(3):219-29. doi: 10.3233/JHD-150163. Link to article on publisher's site
Journal of Huntington's disease
Johnson ES, Chase KO, McGowan S, Mondo E, Pfister EL, Mick E, Friedline RH, Kim JK, Sapp E, DiFiglia M, Aronin N. (2015). Safety of Striatal Infusion of siRNA in a Transgenic Huntington's Disease Mouse Model. UMass Center for Clinical and Translational Science Supported Publications. https://doi.org/10.3233/JHD-150163. Retrieved from https://escholarship.umassmed.edu/umccts_pubs/84